Allegheny Health Network | Strategic Alliance Partners

Allegheny Health Network (AHN) is a physician-led, non-profit healthcare system based in Pittsburgh, Pennsylvania, dedicated to defining a higher standard in care through compassion, respect, and understanding. AHN is committed to providing patients with expert care of the highest quality, with physician leaders shaping care decisions and driving innovation. As an academic institution with 14 hospitals and over 250 physician practices, AHN provides care for complex diagnoses and treatments while actively educating the next generation of medical professionals through its residency and fellowship programs. AHN serves people across Pennsylvania, New York, Ohio, and West Virginia.

AHN is a nationally recognized healthcare network, renowned for quality patient care, accelerating research, and life-saving advances. The network fosters a supportive, collaborative environment across its diverse clinical areas. As part of Highmark Health, one of the nation's most respected health organizations, AHN benefits from significant stability and resources, enabling it to continually enhance patient care and expand its reach. AHN maintains a close-knit work community where each of its 22,000 employees, including 3,000 physicians, residents, and fellows, is valued and recognized.

Connect with us:

Latest from Allegheny Health Network

AHN Cancer Institute Achieves Radiation Oncology Services Accreditation From ASTRO's APEx - Accreditation Program for Excellence

December 08, 2023

Article

Allegheny Health Network Cancer Institute’s (AHNCI) Radiation Oncology program recently attained accreditation from the American Society for Radiation Oncology APEx - Accreditation Program for Excellence® for all 13 of its radiation oncology facilities.

AHN Cancer Institute Unveils State-of-the-Art Skin Cancer Center at West Penn Hospital

November 03, 2023

Article

Allegheny Health Network Cancer Institute unveiled its new, state-of-the-art Skin Cancer Center at West Penn Hospital, featuring a first-in-the-region full-body 3D imaging system that provides custom digital surveillance for skin abnormalities.

AHN West Penn Doctors First in Region to Use New Minimally Invasive Technology to Combat Cancer and Target Hard-to-Reach Tumors

September 19, 2023

Article

Interventional Radiologists at Allegheny Health Network's West Penn Hospital are the first in the region, and among the first in the country, to use a cutting-edge new technology called the Aliya Pulsed Electrical Field system, to target and eradicate cancer cells while preserving healthy adjacent tissues.

Breast Nerve Preservation and Grafting: How Surgeons Can Help Mitigate Sensation Loss

August 01, 2023

Article

More surgeons are having in-depth conversations with their patients with breast cancer and prophylactic patients about the fact that nerves will have to be cut during their mastectomy, how that will impact sensation and quality of life, and how surgeon collaboration and breast neurotization can help restore sensation.

Dr Coopey on the Benefits of Axillary Surgery Omission or De-Escalation in Breast Cancer

June 29, 2023

Video

Suzanne B. Coopey, MD, FACS, discusses the benefits seen with the de-escalation of axillary lymph node surgery for patients with breast cancer, as well as current recommendations for the de-escalation or omission of this procedure.

Persistence Is Key to Success

June 15, 2023

Article

Vinay Edlukudige Keshava, MD, shares the story of his fellowship and provides advice on how to best transition to the next step in an oncologic career.

Dr Champ on the Consideration of Using Radiation Therapy in Breast Cancer

June 02, 2023

Video

Colin E. Champ, MD, discusses the importance of considering the use of radiation therapy for patients with breast cancer and details ongoing research into this arena.

Dr Hilton on Trastuzumab Deruxtecan in HER2+ Metastatic Breast Cancer

June 01, 2023

Video

Christie J. Hilton, DO, discusses the first-line standard of care and changes in the second-line SOC, including key findings from the phase 3 DESTINY-Breast03 trial, in patients with HER2-positive metastatic breast cancer.

Dr Hilton on the Potential Impact of the CompassHER2-pCR Trial in HER2+ Breast Cancer

May 30, 2023

Video

Christie J. Hilton, DO, discusses the potential impact of the ongoing phase 2 CompassHER2-pCR trial for patients with HER2-positive breast cancer.

Improvements in Personalized Medicine Allow for Greater Exploration of Treatment De-escalation in Breast Cancer

May 30, 2023

Article

Suzanne B. Coopey, MD, FACS, discusses the de-escalation of axillary lymph node surgery, shifts in the use of radiation oncology, and changes in the treatment paradigm for HER2-positive breast cancer.

Efforts to Explore Current Therapeutics in Earlier Treatment Lines Continue Across Breast Cancer Subtypes

May 28, 2023

Article

Christie J. Hilton, DO, details the evolving role of trastuzumab deruxtecan in HER2-positive breast cancer and the potential to de-escalate therapy in early-stage disease.

Dr Champ on Boost Radiotherapy in Breast Cancer

May 26, 2023

Video

Colin E. Champ, MD, discusses findings from 2 clinical trials investigating boost radiotherapy plus whole breast radiotherapy following surgery in patients with ductal carcinoma in situ or early-stage breast cancer.

Dr Hilton on the Impact of Trastuzumab Deruxtecan in HER2+ Breast Cancer

May 19, 2023

Video

Christie J. Hilton, DO, discusses the impact of trastuzumab deruxtecan on the treatment of patients with HER2-positive metastatic breast cancer and ongoing research with the agent in this patient population.

AHN Breakthrough

January 03, 2023

Article

Immunotherapy and You: Checkpoint Inhibitors in Gynecologic Cancers

November 30, 2022

Video

In this sixth episode of OncChats: Immunotherapy and You, John Nakayama, MD, and Ali Amjad, MD, highlight the success seen with checkpoint inhibitors in gynecologic cancers, biomarkers of interest, and recent approvals in the space.

Immunotherapy and You: Understanding the PD-L1 Blockade

November 23, 2022

Video

In this fifth episode of OncChats: Immunotherapy and You, John Nakayama, MD, and Ali Amjad, MD, discuss PD-1 blockade, potential biomarkers of response to treatment with immunotherapy, and the potential for these agents in the neoadjuvant setting.

Long-term Survival Data With Immunotherapy in Gynecologic Cancers

November 16, 2022

Video

In this fourth episode of OncChats: Immunotherapy and You, John Nakayama, MD, and Ali Amjad, MD, highlight long-term survival data reported with immunotherapy approaches in patients with gynecologic cancers.

PARP Maintenance Therapy Provides Varying Benefit in Advanced Ovarian Cancer

November 10, 2022

Article

The benefit of PARP maintenance therapy for patients with advanced ovarian cancer differs depending on a number of factors, including the homologous recombination and BRCA mutation status of the tumor.

Immunotherapy and You: The 5 Cs in Gynecologic Cancer

November 09, 2022

Video

In this third episode of OncChats: Immunotherapy and You, John Nakayama, MD, and Ali Amjad, MD, review the 5 C's to consider when conducting research in gynecologic cancers and beyond.

Immunotherapy and You: Gynecologic Treatment Efficacy From a Patient’s Perspective

November 02, 2022

Video

In this second episode of OncChats: Immunotherapy and You, John Nakayama, MD, and Ali Amjad, MD, discuss the safety and efficacy of immunotherapy vs standard chemotherapy in patients with gynecologic cancers.